SCHEMBL9735541

SCHEMBL9735541

CCOC(=O)c1cccc(C)c1OCC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.61
ALDH1A1 P00352 3/20 0.53
HSD17B10 Q99714 1/20 0.53
CDC25B P30305 2/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
CYP1A2 P05177 2/20 0.47
GAA P10253 3/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 2/20 0.46
HTT P42858 2/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14974980 0.89 TSHR (0.56) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL16959103 0.88 TSHR (0.46) TSHRALDH1A1HSD17B10GAAMAPT
SCHEMBL11678098 0.88 TSHR (0.63) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL14974491 0.87 TSHR (0.57) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL28393362 0.87 TSHR (0.44) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL14975222 0.86 TSHR (0.53) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL14992204 0.86 TSHR (0.58) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL14974961 0.86 TSHR (0.53) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL15312293 0.85 TSHR (0.59) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL14974972 0.85 ALDH1A1 (0.59) TSHRALDH1A1HSD17B10MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360085-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC (US) 2024-10-31 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-12030857-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2024-07-09 US disclosed
US-20220363648-A1 Glucose Uptake Inhibitors KADMON CORPORATION, LLC 2022-11-17 US disclosed
US-5147645-A Insecticides, miticides, nematocides BASF AKTIENGESELLSCHAFT (DE) 1992-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030857-B2 Glucose uptake inhibitors SLC2A1, SLC2A4, SLC2A2 TSHR 3168/4885ALDH1A1 1422/4885HSD17B10 749/4885
US-20220363648-A1 Glucose Uptake Inhibitors SLC2A1, SLC2A4, SLC2A2 TSHR 3168/4885ALDH1A1 1422/4885HSD17B10 749/4885
US-20240360085-A1 Glucose Uptake Inhibitors SLC2A3, SLC2A1, SLC2A4 TSHR 2854/4885ALDH1A1 1565/4885HSD17B10 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.